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Background: The issue of resistance in malarial infection makes development of novel drugs a necessity. An
alternative source for discovering such drugs is natural products. Croton macrostachyus H. (Euphorbiaceae) is used
in Ethiopian folklore medicine for the treatment of malaria and found to possess antimalarial activity in vitro.
However, no further scientific investigations have been carried out to substantiate the claim. This study therefore
aimed at investigating the in vivo antiplasmodial activity of 80% methanol extract and solvent fractions of the
leaves of Croton macrostachyus H. in rodent model of malaria.
Methods: A rodent malaria parasite, Plasmodium berghei, was used to inoculate healthy male Swiss Albino mice of
age 6–8 weeks and weight 23–27 g. A hydro-alcoholic crude extract and the solvent fractions (chloroform,
methanol and aqueous) were administered at different doses 200, 400 and 600 mg/kg. Parameters, including
parasitemia, survival time, body weight, temperature, and packed cell volume were then determined using standard
tests such as Peter’s and Rane’s test.
Results: Chemoprotective effect exerted by the crude extract and fractions ranged between 44-91% and 12-76%,
respectvely. The chemotherapeutic effect of the crude extract and chloroform fraction was in the range of 39-83%
and 66-82%, respectively. Maximum effect in both tests was observed with the larger dose of the crude extract and
chloroform fraction. The crude extract prevented loss of weight and reduction in temperature but did not affect
packed cell volume. However, the chloroform fraction did also reverse reduction in packed cell volume due to the
absence of saponins in the fraction.
Conclusions: The results collectively indicate that the plant has a promising antiplasmodial activity against
Plasmodium berghei, which upholds the earlier in vitro findings as well as its folkloric use. Thus, it could be
considred as a potential source to develop new antimalarial agents.
Keywords: Antimalarial activity, Plasmodium berghei, Croton macrostachyus, Chloroform fraction, In vivo studyBackground
Malaria is a major public health concern in the world,
causing an estimated 0.7-1 million deaths per year. Ap-
proximately, half of the world’s population is at risk of
malaria [1,2] and the vast majority of cases (78%) occur
in the African region followed by Southeast Asia (15%)* Correspondence: ephrem.engidawork@aau.edu.et
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unless otherwise stated.and Eastern Mediterranean regions (5%) [3]. Even though
the disease is preventable and curable, it is still one of the
greatest global public health challenges especially in sub-
Saharan Africa [4].
There is broad consensus on the need for develop-
ment of new agents, owing to the increasing resist-
ance of the parasite to available agents. Antimalarial
drug development can follow several strategies, ran-
ging from minor modifications of existing agents totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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gets [5]. Natural products are the source of the two
most important drugs currently available to treat
severe falciparum malaria, quinine and artemisinin
derivatives. In case of artemisinin, relatively simple
chemical modifications of the natural parent com-
pound have led to the synthesis of a series of highly
potent antimalarials [6,7]. The development of these
two important drugs from natural sources and the
utilization of many plants traditionally in various
parts of the world triggered the search for new anti-
malarial drugs of natural origing using in vitro and
in vivo studies.
Croton macrostachyus H. (Euphorbiaceae) is com-
monly found on forest edges along rivers, around lakes,
woodlands, wooded grasslands and along roadsides. It is
native to Eritrea, Ethiopia, Kenya, Nigeria, Tanzania and
Uganda [8,9]. In Ethiopia, it is used for the treatment of
malaria by the Shinasha, Agew-awi and Amhara people
[10]. Recently, fourteen secondary metabolites have been
isolated from Croton macrostachyus and five of them
were isolated from the genus for the first time. The
compunds include phenolics and triterpenes of the
lupane and hopane groups [11].
Ethnobotanical/pharmacological studies revealed that
Croton macrostachys has a wide range of activities.
The plant has shown a promising antimicrobial [12],
antidiabetic [8], purgative and anti-inflammatory ef-
fects [13]. The ethyl acetate extract of the stem bark
[14] as well as the methanol and dichloromethane ex-
tracts of the leaves and stem bark of the plant have
been demonstrated to possess significant antibacterial
and antifungal activities [15,16]. An in vitro study of
the fruit extract indicated that the plant had a good
antiplasmodial activity [17]. Moreover, the methanol
leaf extract of Croton macrostachyus exhibited larvi-
cidal activity against late third instar larvae of Ano-
pheles arabiensis Patton, a potent malaria vector in
Ethiopia [18].
About 80% of the Ethiopian population use trad-
itional medicine due to the cultural acceptability of
healers, the relatively low cost of traditional medicine
and the difficulty of accessing modern health facilities
[19]. The studies conducted on the traditional medi-
cinal plants in Ethiopia are, however, scanty when
compared with the multiethnic cultural diversity as
well as the diverse flora of Ethiopia. Although re-
cently there are efforts to identify and screen antimal-
arial herbs used in the ethnomedicine practice of the
country, the studies done are very limited and not
fully exploratory. Most of them focused on reviewing
the ethnobotanical uses of the plant rather than
pharmacological screening [20]. Thus, based on eth-
nobotanical and in vitro studies mentioned above, thepresent study evaluated the in vivo antimalarial activ-
ity of the crude extract and solvent fractions of Cro-
ton macrostachyus H.Methods
Plant material
Fresh leaves of Croton macrostachyus H. were collected
in October 2010 from Shindi district of Amhara regional
state, 420 km North West of Addis Ababa. The fresh
leaves were wrapped with plastic sheets during transpor-
tation. The plant was identified as Croton macrostachyus
by a taxonomist and a voucher specimen was deposited
(No. LB 001) at the National Herbarium, College of
Natural Sciences, Addis Ababa University for future
reference.Animals and parasite
Male Swiss albino mice (age 6–8 weeks and weight of
23–27 g) bred and maintained at the Ethiopian Health
Nutrition and Research Institute were used. They were
maintained under standrad condition (temperature of
22 ± 3°C, relative humidity of 40-50% and 12 h light/
12 h dark cycle), with food and water ad libitum in the
animal house of Akililu Lemma Institute of Pathobiol-
ogy, Addis Ababa University. Animals were acclima-
tized for one week to the experimental environment.
The care and handling was according to international
guidelines for the use and maintenance of experimental
animals [21] and the School of Pharmacy Ethics com-
mittee approved the protocol.
Chloroquine sensitive strain of Plasmodium berghei
(ANKA) obtained from the Department of Biology,
College of Natural Sciences, Addis Ababa University was
used. The parasites were maintained by serial passage of
blood from infected mice to non-infected ones on
weekly basis.Extraction
Crude extract
The leaves were air dried at room temperature under
shade and reduced to appropriate size by grinding
with an electric mill. A total of (600 g) dried leaves
were extracted by maceration (100 g of dried leave in
600 ml of 80% methanol) for 72 h. The extraction
process was facilitated by using an orbital shaker at
120 rpm. The mixture was first filtered using gauze
and then with Whatman filters paper No. 1 (What-
man®, England). The residue was re-macerated for an-
other 72 h twice and filtered. The combined filtrates
were then dried by rotary evaporator (Buchi Rota
vapor, Switzerland) at a temperature of 40°C. After
drying, a total of 74.4 g of dry extract was harvested
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until use.
Solvent fractionation
The crude extract, after defatted with petroleum ether,
was subjected to successive extraction in soxhlet appar-
atus using solvents with differing polarity (chloroform,
absolute methanol and distilled water). The dried crude
hydroalcoholic extract was placed in a cellulose thimble
in an extraction chamber, which was placed on top of a
collecting flask beneath a reflux condenser. Chloroform
was first added to the flask, and the set up was heated
under reflux. When a certain level of condensed solvent
accumulated in the thimble, it was siphoned into the
flask beneath and continued for 3 days [22] to get the
chloroform fraction. The residue left in the thimble was
next extracted using methanol following the same pro-
cedure as above to get the methanol fraction. The
chloroform fraction was air dried at room temperature,
while the methanol fraction was removed by using
rotary evaporator. The residue left inside the thimble
from the two solvent fractions was macerated in
Erlenmeyer flask using distilled water to get the aque-
ous fraction. The aqueous fraction was then con-
centrated in a water bath and further dried using a
lyophilizer (Operan, Korea vacuum limited, Korea). The
yield of the dried fraction was 11.2%, 27.6% and 44.6%
for the chloroform, methanol and aqueous fractions, re-
spectively. The dried fractions were then transferred
into separate vials and stored at −20°C until use.
Acute toxicity testing
Twelve female Swiss albino mice were randomly divided
into 2 groups of 6 mice per group. After being fasted for
2 h [21,23], mice in the first group were given 2 g/kg
and the second group 5 g/kg of the crude extract orally
and observed for any signs of toxicity daily for 14 days
to assess safety of the extract. Animals were observed
for gross changes such as loss of appetite, hair erection,
lacrimation, tremors, convulsions, salivation, diarrhoea,
mortality and other signs of overt toxicity [21].
In vivo antimalarial tests
Parasite inoculation
Albino mice previously infected with Plasmodium ber-
ghei and having parasitemia level of 20-30% were
used as donor. The donor mice were then sacrificed
by decapitation and blood was collected by cardiac
puncture into heparinized vacutainer tube containing
0.5% trisodium citrate. The blood was then diluted
with physiological saline (0.9%) based on parasitemia
level of the donor mice and the red blood cell (RBC)
count of normal mice [24], in such a way that 1 ml
blood contains 5 × 107 infected RBCs. Each mousewas then given 0.2 ml of this diluted blood intraperi-
toneally, which contained 1 × 107 Plasmodium berghei
infected RBCs.
Grouping and dosing of animals
For evaluating the crude extract, infected mice were ran-
domly divided into five groups of 6 mice per group. Group
I-III were treated with the crude extract of Croton macro-
stachyus at 200 mg/kg (CM200), 400 mg/kg (CM400) and
600 mg/kg (CM600), repectively. The remaining two
groups served as negative and positive controls and ad-
ministered distilled water (CON) (2 ml/100 g) [15] and
chloroquine 25 mg/kg (CQ25), respectively.
The study on the fractions was conducted using thirty
mice for each fraction. Mice were randomly assigned
into three treatment groups and two controls, six mice
per group for each fraction. Negative controls were ad-
ministered the vehicle used for reconstitution (Tween 80
2% v/v in water for the chloroform and methanol frac-
tions or distilled water for the aqueous fraction) (CON).
Treatment groups were given the fractions at a dose of
200 mg/kg, 400 mg/kg and 600 mg/kg dissolved in the
respective vehicle. The last group was treated with the
standard, CQ25. Doses were selected based on acute
toxicity studies. Volume administered was 0.2 ml and
gavage was used for oral administration.
The 4 day suppressive test
This test was used to evaluate the schizontocidal activity
of the extract and the fractions against Plasmodium ber-
ghei infected mice according to the method described by
Peter et al. [25]. Infected mice were randomly divided
into their respective group as described under grouping
and dosing. Treatment was started three hours after
mice had been inoculated with the parasite on day 0 and
then continued daily for four days from day 0 to day 3.
After treatment was completed, thin blood film was pre-
pared from the tail of each animal on day 4 to determine
parasitemia and percentage inhibition. In addition, each
mouse was observed daily for determination of survival
time.
Rane’s test
Evaluation of the curative potential of the crude ex-
tract and the most active fraction in Peter’s test was
carried out according to the method described by
Ryley and Peters [26]. On Day 0, standard inocula of
1 × 107 infected erythrocytes were inoculated in mice
intraperitoneally. Seventy-two hours later, mice were
randomly divided into their respective groups and
dosed accordingly once daily for five days. Geimsa
stained thin blood film was prepared from the tail of
each mouse daily for 5 days to monitor parasitemia level.
Mean survival time for each group was determined
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(days) of mice starting from date of infection over a period
of 30 days (D0-D29).
Packed cell volume measurement
Packed cell volume (PCV) was measured to predict the
effectiveness of the test extract and fractions in prevent-
ing hemolysis resulting from increasing parasitemia as-
sociated with malaria. Heparinized capillary tubes were
used for collection of blood from tail of each mouse.
The capillary tubes were filled with blood up to ¾th of
their volume and sealed at the dry end with sealing clay.
The tubes were then placed in a micro-hematocrit cen-
trifuge (Gelma Awhksley, England) with the sealed end
outwards and centrifuged for 5 min at 11,000 rpm. The
tubes were then taken out of the centrifuge and PCV
was determined using a standard Micro-Hematocrit
Reader (Hawksley and Sons, England). PCV is a measure
of the proportion of RBCs to plasma and measured be-
fore inoculating the parasite and after treatment using
the following relationship:
PCV ¼ Volume of erythrocytes in a given volume of blood
Total blood volume
Parasitemia measurement
Thin smears of blood were made from the tail of each
mouse on day 4 for Peter’s test and on day 3–7 for
Rane’s test. The smears were applied on microscope
slides (76 × 26 mm) (Menzel-Glaser, Germany), fixed
with absolute methanol for 15 min and stained with 10%
Geimsa stain at pH 7.2 for 15 min. The stained slides
were then washed gently using distilled water and air
dried at room temperature. Two stained slides for each
mouse were examined under Olympus microscope
(CHK2-F-GS, Taiwan) with an oil immersion nosepiece
of 100× magnification. Three different fields on each
slide were examined to calculate the average parasitemia
as shown below [27].
% Parasitemia ¼ Number of parasitized RBC
Total number of RBC
 100
Finally, percent parasitemia suppression of the extracts
was compared with respect to the controls and para-
sitemia suppression was calculated using the following
formula [28].% suppression ¼ mean parasitemia of negative cont
mean parasitemMonitoring of body weight and temperature changes
For Peter’s test, body weight of each mouse was mea-
sured before infection (day 0) and on day 4 using a
sensitive digital weighing balance (Mettler Toledo,
Switzerland). Rectal temperature was also measured by a
digital thermometer before infection, four hours after in-
fection and then daily. For Rane’s test, body weight and
temperature were measured before infection and from
day 3–7 after infection. In order to rule out the effect of
the extract on body weight, temperature and PCV; the
crude extract was administered to healthy mice at the
doses used for four days. The extract was found to have
no effect on temperature and PCV. However, the larger
dose of the crude extarct (CM600) was found to signifi-
cantly reduce body weight of healthy mice.
Phytochemical screening
The crude extract and solvent fractions were screened
for the presence of different secondary metabolites fol-
lowing standard procedures [29-32].
Data analysis
Data are expressed as mean ± standard error of mean
(SEM). Data were analyzed using Windows SPSS Ver-
sion 16.0. One-way analysis of variance (ANOVA)
followed by Tukey’s HSD post-hoc test was used to de-
termine statistical significance for comparison of parasit-
emia suppression, weight, PCV, rectal temperature and
survival time among groups. P-value of less than 0.05
was considered statistically significant.
Results
Acute toxicity study
The acute toxicity study indicated that the extract
caused no mortality in both doses (2 and 5 g/kg) within
the first 24 h as well as for the following 14 days. Phys-
ical and behavioural observations of the experimental
mice also revealed no visible signs of overt toxicity like
lacrimation, loss of appetite, tremors, hair erection, sali-
vation, diarrhoea and the like. This suggests that LD50
of the extract is greater than 5 g/kg.
Effect on four day suppressive test
Crude extract
The results of the study showed that the extract dis-
played chemosuppressive activity against Plasmodium
berghei (Table 1). Percentage inhibition analysis indi-
cated that the extract produced a dose-dependentrol−mean parasitemia of treated group
ia of negative control
 100
Table 1 Parasitemia and survival time of infected mice treated with crude extract and solvent fractions of Croton
macrostachys in the 4 day suppressive test
Extract Animal group Parasitaemia level % suppression Survival date
Crude extract
CON 32±0.97 - 7±0.36
CM200 18±1.73 44a3,b3,c3 10±0.33a1,b3,c3
CM400 7±0.31 78a3,b1,c3 14±0.42a3,b3,c3
CM600 3±0.40 91a3 18±0.60a3,c3
CQ25 0.0a3 100 30±0a3
Chloroform fraction
CON 30.43±0.61 - 7.34±0.42
CF200 15.40±0.43 49.4a3,c3 9.00±0.68c3
CF400 10.30±0.58 66.2a3,c3,e3 13.34±1.25a3,c3,e1
CF600 7.34±0.15 75.9a3,c3,d3,e3 16.50±1.08a3,c3,e3
CQ25 0.00±0.00 100.00a3 29.67±0.34a3
Methanol fraction
CON 34.33±1.62 - 6.84±0.17
MF200 21.61±0.54 37.1a3,c3 8.83±1.14c3
MF400 16.30±0.71 52.5a3,c3,e2 8.50±0.56c3
MF600 12.28±0.52 64.2a3,c3,d1,e3 10.00±1.15a1,c3
CQ25 0.00±0.00 100.00a3 30.00±0.00a3
Aqueous fraction
CON 37.47±0.84 - 7.00±0.25
AF200 33.03±0.94 11.8a2,c3 7.84±0.60c3
AF400 26.27±0.69 29.9a3,c3,e3 8.34±0.42c3
AF600 22.94±0.79 38.8a3,c3,d3,e3 9.17±0.31a2,c3
CQ25 0.00±0.00 100.00a3 30.00±0.00a3
Data are expressed as mean ± SEM; n = 6; a, compared to control; b, to 600 mg/kg; c, to CQ25mg/kg; d, to 400 mg/kg; e, 200 mg/kg: 1p<0.05, 2p<0.01, 3p<0.001;
CF = Chloroform fraction, CQ = chloroquine, MF, methanol fraction, AF, aqueous fraction, CON = Control, CM, crude extract of Croton macrostachys. Numbers refer
to dose in mg/kg.
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compared to CON mice. CM600 exhibited a significant
parasite suppression compared to other doses of the ex-
tract and the activity was almost comparable to that of
CQ25 (Table 1). The extract was also capable of signifi-
cantly increasing survival time at all doses compared to
controls, but the effect was significantly lower than
CQ25.
Analysis of rectal temperature revealed that 80% meth-
anolic extract of Croton macrostachys caused significant
attenuation of reduction in temperature of Plasmodium
berghei infected mice in a dose-dependent manner
(p<0.01 for CM200 & CM400, p<0.001 for CM600).
Both CM200 and CM400 had a comparable effect to
CQ25, while CM600 appeared to have a better effect,
although the result was not statistically significant
(Table 2). The extract averted loss of weight associated
with infection at all dose levels compared to CON mice.
However, the increase in body weight was not found to
be dose-dependent, as maximum effeect was obsreved
with CM400 and minimum with CM200. There were no
detectable differences in preventing weight reduction as-
sociated with parasitemia between the extracts as well asbetween the extract and CQ25 (Table 2). Neither the ex-
tract nor the standard prevented reduction of PCV when
compared to CON animals.
Solvent fractions
All the fractions dose-dependently reduced parasitemia
level compared to CON group, although the extent of
reduction was less than that of CQ25, which produced
100% suppression (Table 1). The rank order of chemo-
suppression of the solvent fractions was chloroform
(75.9%) > methanol (64.2%) > aqueous (38.8%). Survival
date was significantly prolonged (p<0.001) by the larger
and middle doses of the chloroform fraction but only
the larger dose of the methanol (p<0.05) and aqueous
(p<0.01) fractions was capable of significantly increasing
survival date compared to CON mice.
Body weight reduction caused by inoculation of the
parasite was not significantly ablated by both chloroform
and aqueous fractions. By contrast, all doses of the
methanol fraction significantly prevented (p<0.001) body
weight reduction. PCV reduction was dose-dependently
attenuated by all doses of the chloroform fraction, but
no detectable changes were noted with the other two
Table 2 Temperature, weight and packed cell volume of infected animals treated with crude extract and solvent
fractions of Croton macrostachys in the 4 day suppressive test
Extract Animal
group
Temperature Weight Packed cell volume
D0 D4 % change D0 D4 % change D0 D4 % change
Crude extract CON 37.2±0.19 37.2±0.19 −2 26.0±0.18 24.0±0.43 −15.5 55±0.33 53±0.26 −3.6
CM200 37.5±0.08 37.2±0.07 −0.8a2 26.1±0.12 25.3±0.34 −5.2a1 53±1.34 53±1.48 0.0
CM400 37.1±0.11 37.1±0.11 0.5a2 26.2±0.11 25.9±0.15 −0.6a3 54±0.50 55±0.70 1.8
CM600 37.0±0.15 37.0±0.15 1.3a3 26.2±0.17 25.7±0.22 −2.8a2 54±0.55 56±0.84 3.5
CQ25 37.2±0.08 37.2±0.08 0.2a2 26.1±0.09 25.5±0.05 −2.4a2 53±0.55 55±0.42 3.8
Chloroform fraction CON 37.3±0.42 32.9±0.21 −11.76 27.9±0.82 26.8±1.15 −4.00 53.3±1.46 49.7±1.61 −6.73
CF200 36.9±0.37 36.3±0.47 −1.59a3 27.17±0.64 25.15±1.16 −7.43b3 51.7±1.78 51.1±1.1 −1.14a1
CF400 37.5±0.32 37.4±0.23 −0.48a3 27.7±1.16 26.8±1.08 −3.82b2 52.2±1.25 52.2±1.16 0.00a2
CF600 37.7±0.49 37.4±0.39 −0.93a3 28.1±1.20 27.9±1.12 −0.89b1 51.7±1.82 53.3±1.90 3.23a3
CQ25 37.4±0.27 37.5±0.26 0.32a3 26.7±0.51 27.3±0.83 2.36a2 53.2±0.48 53.9±0.62 1.35a2
Methanol fraction CON 37.3±0.21 35.4±0.17 −5.15 31.6±0.47 30.3±0.89 −3.83 53.8±1.61 52.3±1.05 −2.80
MF200 37.7±0.29 35.2±0.71 −6.63b3 26.6±0.47 27.2±0.54 2.44a3 53.2±0.98 50.4±0.70 −5.17b3
MF400 37.9±0.36 34.4±0.48 −9.24b3 26.8±0.55 28.1±0.59 4.43a3 52.8±0.96 51.2±0.90 −3.00b2
MF600 38.0±0.15 34.7±0.23 −8.73b3 28.1±0.89 29.4±0.81 4.52a3 50.9±1.28 51.1±1.47 0.25
CQ25 36.9±0.25 37.2±0.60 0.68a3 30.1±0.93 30.5±0.83 1.33a2 54.8±1.16 55.7±0.98 1.68a1
Aqueous fraction CON 37.7±0.13 34.2±0.28 −9.30 31.7±0.57 30.4±0.65 −3.94 55.8±1.17 53.9±1.25 −3.40
AF200 37.1±0.46 34.9±0.32 −5.90b2 30.8±0.79 30.7±0.54 −0.39b1 56.8±0.96 55.3±0.54 −2.64b1
AF400 36.7±0.25 34.9±0.27 −5.20b2 29.2±0.86 28.9±0.75 −1.04b1 54.4±1.85 54.2±0.21 −0.46
AF600 36.6±0.35 34.9±0.56 −4.97b2 30.0±1.04 29.0±0.90 −3.26b2 56.4±1.14 55.8±0.77 −1.19b1
CQ25 36.9±0.35 36.6±0.26 −1.00a3 28.1±1.08 28.8±1.18 2.56a2 55.5±0.79 56.1±0.55 1.04a1
Data are expressed as mean ± SEM; n = 6; a = compared to control, b = to chloroquine 25 mg/kg; 1p< 0.05; 2p<0.01, 3p<0.001; D0 = pre-treatment value on
day 0, D4 = post-treatment value on day four, CF = Chloroform fraction, CQ = chloroquine, MF, methanol fraction, AF, aqueous fraction, CON = Control, CM, crude
extract of Croton macrostachys. Numbers refer to dose in mg/kg.
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significantly (p<0.001) prevented the reduction in rectal
temperature caused by escalating parasitemia and the ef-
fect was comparable to that observed with CQ25 mice
(Table 2).
Effect on curative test
Crude extract
The crude extract dose-dependently reduced (p<0.001 in
all cases) parasitemia by 39, 69 and 83% for CM200,
CM400 and CM600, respectively, compared to CON
mice (Table 3). The inhibition obtained by CQ25 was sig-
nificantly higher than CM200 (p<0.001) and CM400
(p<0.05) but, no apparent difference was observed with
CM600. Survival time was not altered by CM200 but sig-
nificantly increased by CM400 (p<0.001) and CM600
(p<0.001), however, the increase achieved with the ex-
tract was no match to that of CQ25 (Table 3). Rectal
temperature analysis indicated that the extract had a sig-
nificant preventive effect on the reduction in temperature
at all doses compared to CON animals. Comparison of
the doses amongst themselves as well as with CQ25,however, did not reveal any apparent changes (Table 4).
Similar to the 4 day suppressive test, all doses of the ex-
tract failed to show any protective activity against the re-
duction in PCV (Table 4). The extract exhibited a
preventive effect in weight reduction in infected mice at
all dose levels compared to CON mice. However, the
increase in body weight was not dose-dependent. No
significant difference was noted in prevention of parasite-
induced weight reduction when comparison was per-
formed amongst the extract doses as well as with CQ25
(Table 4).
Solvent fractions
The fraction with the highest antimalarial activity
(chloroform fraction) in the four day suppressive test
was further evaluated for its effect on established para-
site infection. Chloroform fraction exhibited a dose-
dependent reduction (p<0.001) of parasitemia compared
to CON animals in the Rane’s test (Table 3). Maximum
inhibition (82.3%) was attained with 600 mg/kg dose of
the fraction. On the other hand, CQ25 cleared the para-
site to undetectable level on day 7 and the reduction in
Table 3 Parasitaemia and survival of infected animals treated with crude extract and chloroform fraction of Croton
macrostachys in the Rane’s test
Extract Group Day 3 Day 4 Day 5 Day 6 Day 7 % inhibition Survival date
Crude extract CON 9±0.15 16±0.13 14±0.23 31±0.61 36±1.1 - 6±0.31
CM200 12±0.36 28±1.20 26±0.32 25±0.16 22±0.19 39a3,b3,c3 7±0.31b3,c3
CM400 11±0.43 19±0.95 16±0.85 14±0.54 11±0.95 69a3,c1 12±0.47a3,b3,c3
CM600 10±0.32 14±0.56 11±0.47 8±0.41 7±0.78 83a3 16±0.42a3,c3
CQ25 11±0.22 5±0.09 2±0.56 0 0.00±0.00 100a3 30±0a3
Chloroform fraction CON 21.8±0.58 26.6±0.90 33.1±0.81 40.7±0.67 54.6±1.34 - 7.2±0.31
CF200 20.8±0.83 20.8±0.66 20.2±0.92 19.8±0.50 18.5±0.63 66.2a3,c3 7.5±0.34c3
CF400 22.7±0.63 21.2±0.51 17.4±0.45 15.4±0.49 13.5±0.80 75.3a3,c3,e2 10.3±0.76a2,d3
CF600 21.8±0.79 20.9±0.62 15.4±1.02 11.5±0.45 9.7±0.65 82.3a3,c3,d1,e3 12.3±0.72a3,c3,e3
CQ25 20.8±0.85 15.6±1.02 5.5±0.28 1.5±0.29 0.00±0.0 100a3 30.0±0.0a3
Data are expressed as mean ± SEM; n = 6: a, compared to control; b, to 600 mg/kg; c, to CQ 25; d, to 400 mg/kg; e, to 200 mg/kg: 1p<0.05, 2p<0.01, 3p<0.001;
CF = Chloroform fraction, CQ = chloroquine, MF, methanol fraction, AF, aqueous fraction, CON = Control, CM, crude extract of Croton macrostachys. Numbers refer
to dose in mg/kg.
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http://www.biomedcentral.com/1472-6882/14/79parasitaemia was significantly higher (p<0.001) com-
pared to CON as well as all doses of the fraction.
As shown in Table 3, lower dose of chloroform frac-
tion was not associated with significant prolongation of
survival time. Although the middle (p<0.01) and larger
(p<0.001) doses of the fraction did significantly prolong
survival time compared to CON mice, the effect was still
much lower (p<0.001) than attained by CQ25. All doses
of the fraction as well as CQ25 were shown to signifi-
cantly (p<0.001) prevent the reduction in temperature
compared to CON group. CQ25 halted temperature
dropping significantly compared to CF200 (p<0.05).
However, there was no significant difference compared
to the middle and larger doses of the fraction (Table 5).Phytochemical screening
Phytochemical screening of the hydroalcoholic crude ex-
tract of the leaves of Croton macrostachyus revealed the
presence of alkaloids, saponins, phenolic compounds,
cardiac glycosides, tannins, terpenoids and flavonoids.
Anthraquinones and phlabotannins were, however, ab-
sent from the crude extract. Phytochemical composition
of the different fractions is depicted in Table 6. TheTable 4 Rectal temperature, weight and packed cell volume o
macrostachys in the Rane’s test
Animal group T0 T4 % change W0
CON 37.4±0.14 36.6±0.05 −2.2 26.2±0.21
CM200 37.3±0.08 37.2±0.08 −0.2a2 26.3±0.11
CM400 37.4±0.09 37.4±0.04 0.0a3 26.4±0.11
CM600 37.3±0.09 37.4±0.03 0.2a3 26.6±0.06
CQ25 37.4±0.18 37.3±0.13 −0.2a2 26.5±0.04
Data are expressed as mean ± SEM; n = 6; a,compared to controls, 1p<0.05, 2p< 0.0
T, temperature; PCV, packed cell volume; 0 refers at day 0 and 4 to day 4. Numbersmethanol fraction appeared to be rich in secondary me-
tabolites compared to the other two fractions.
Discussion
The in vivo model was employed for this study because
it takes into account the possible prodrug effect and pos-
sible involvement of the immune system in eradication
of infection [24]. Plasmodium berghei ANKA was used
in the prediction of treatment outcomes [33] and hence
it was an appropriate parasite for the study. Moreover,
several conventional antimalarial agents such as chloro-
quine, halofantrine, mefloquine and more recently arte-
misinin derivatives have been identified using rodent
model of malaria [34].
The 4 day suppressive test, which mainly evaluates the
antimalarial activity of candidates on early infections,
and Rane’s test, which evaluates the curative capability
of candidate extracts on established infections, are com-
monly used for antimalarial drug screening. In both
methods, determination of percent inhibition of parasit-
emia is the most reliable parameter. A mean parasitemia
level ≤ 90% to that of mock-treated control animals usu-
ally indicates that the test compound is active in stand-
ard screening studies [35].f infected animals treated with crude extract of Croton
W4 % change PCV0 PCV4 % change
22.1±0.43 −7.7 54±0.31 53±0.21 −4.9
25±0.16 −3.1a1 53±0.31 52±0.40 −1.9
26.3±0.05 −1.1a3 52.5±0.43 53±0.22 0.9
25.9±0.05 −1.8a2 52±0.31 53±0.44 1.9
25.9±0.04 −2.3a2 52.5±0.42 53±0.21 2.4
1, 3p< 0.001; CM, crude extract of Croton macrostachys; W, weight;
refer to dose in mg/kg.
Table 5 Effect of the chloroform fraction of Croton macrostachyson on rectal temperature of Plasmodium berghei
infected mice in the Rane’s test
Group Day 0 Day 3 Day 4 Day 5 Day 6 Day 7
Control 37.25±0.21 34.05±0.15 34.08±0.19 33.48±0.26 33.53±0.21 32.75±0.16
CM200 37.48±0.3 33.38±0.21 34.48±0.33 34.76±0.27 35.62±0.26 36.43±0.24a3,b1
CM400 37.48±0.22 33.38±0.38 34.53±0.37 34.15±0.23 36.05±0.25 36.62±0.21a3
CM600 37.50± 0.21 33.64±0.32 33.91±0.26 35.74±0.14 36.50±0.28 36.91±0.13a3
CQ25 37.32±0.23 33.92±0.32 34.67±0.24 35.65±0.29 37.13±0.19 37.40±0.19a3
Data are expressed as mean ± SEM for six mice per group; a = compared to controls, b = to chloroquine 25 mg/kg; 1 = p<0.05; 3=p<0.001, CQ = chloroquine.
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parasitemia measured in the 4 day test was reduced by
the crude extract in Plasmodium berghei infected mice,
pointing to the fact that the plant is endowed with anti-
malarial activity. Evidence comes for this assertion from
studies that reported antimalarial activity of other spe-
cies of the same genus such as Croton zambesicus [36].
Among the fractions, the chloroform and methanol frac-
tions were found to possess higher blood schizontocidal
activity than the aqueous fraction. This was evident from
the chemosuppression obtained during the four day
suppressive test, suggesting the possible localization of
the active ingredients in these two fractions. Alkaloids,
phenolic compounds and terpenoids present in these
fractions could be responsible for their antimalarial ac-
tivity. The alkaloids are known to possess antiplasmodial
properties, the most famous being quinine. The highest
antimalarial activity of the chloroform fraction was
found to be similar with other reports that came out
from in vitro [37] and in vivo [38] studies. The phyto-
chemical constituents of chloroform and methanol frac-
tions may have an individual or synergistic effect to
exert their antimalarial activity. But traces may be found
in the aqueous fraction, which could explain its lower
antimalarial activity. Crude extract of Croton macrosta-
chys is reported to possess in vitro antiplasmodial activ-
ity [17] as well as larvicidal property [18]. Moreover,Table 6 Phytochemical constituents of crude extract and











Alkaloids + + + +
Saponins + - + +
Phenolic compounds + + + -
Cardiac glycosides + - + -
Tannins + - + +
Flavonoids + - + -
Terpenoids + + - -
Anthraquinones - - - -
Phlobatannins - - - -
-, absent; +, present.antimicrobial activity has been attributed to the crude
extract [15,16,39], where the chloroform and butanol
fractions showing greater growth inhibitory, while the
aqueous fraction lacking any growth inhibition effect
[40]. Drugs with antibacterial activity such as tetracyc-
line and its derivatives are employed in the treatment of
malaria. These observations further reinforce the notion
that compounds responsible for antimalarial activity of
the plant might be concentrated in non-polar and semi-
polar fractions.
Anemia, body weight loss and body temperature re-
duction are the general features of malaria-infected mice
[41]. So, an ideal antimalarial agents obtained from
plants are expected to prevent body weight loss in in-
fected mice due to the rise in parasitemia. Despite the
fact that the increase in weight was not consistent with
increase in dose, the crude extract of Croton macrosta-
chys significantly prevented weight loss associated with
increase in parasitemia level. The preventive effect de-
clined at the highest dose (CM600) which is consistent
with the results of the parallel sub-acute toxicity study
carried out to rule out the effect of the extract on the
measured parameters. The fact that the preventive effect
decreased with increasing dose might indicate that the
plant could have appetite suppressive effect at higher
doses. This appetite suppressive activity might be as-
cribed to saponins, flavonoids, glycosides and phenolic
compounds found in the crude extract [42]. Unlike the
crude extract, the chloroform and aqueous fractions did
not protect animals from body weight loss but the
methanol fraction did. This suggests the possibility of
the localization of appetite suppressing components in
these fractions [43] and nutrients and other immuno-
modulatory substances in the methanol fraction [33].
A decrease in the metabolic rate of infected mice occurs
before death and is accompanied by a corresponding de-
crease in internal body temperature [44]. Ideally, the rectal
temperature decreases as parasite level escalates. Active
compounds should prevent the rapid dropping of rectal
temperature. The crude extract and the chloroform frac-
tion did have protective effects against temperature reduc-
tion, which reflects constituents responsible for this effect
were likely found in this fraction.
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crude extract and fractions in preventing hemolysis due
to escalating parasitaemia level. The underlying cause of
anemia includes the following mechanisms; the clear-
ance and/or destruction of infected RBCs, the clearance
of uninfected RBCs, and erythropoietic suppression and
dyserythropoiesis. Each of these mechanisms has been
implicated in both human and mouse malarial anemia
[45]. One could note that the chloroform fraction was
the only one that ablated PCV reduction. This observa-
tion is consistent with studies conducted on chloroform
fraction of other plants, including Dodonea Angustifolia
[46]. Failure of the crude extract and the two fractions
to reverse PCV reduction could probably be related to
the presence of saponins in the extract, which are known
to have strong hemolytic effects [46].
In the curative test, blood samples were taken and
smears prepared daily to evaluate the curative ability
of the extract. As indicated in the results section, all
doses of the crude extract and fractions brought
about reduction of parasitemia after second dose,
however, the standard drug chloroquine started its ac-
tivity right after the first dose. This delay of activity
may be indicative of the need for a loading dose or
the extract might have a delayed onset of action. The
curative effect of chloroform fraction occurred in a
dose-dependent manner, with the highest suppression
observed with its higher dose, and this is in line with
previous reports [38,47]. Furthermore, the chloroform
fraction prolonged the mean survival time in estab-
lished parasite infection, which is also concordant
with the study conducted on Melanthra scandens
[38]. Taken together, the results obtained from the
Rane’s test suggest that the chloroform fraction has
therapeutic efficacy against established malaria parasite.
This property is additive to the suppressive activity
and it may be possible to consider the plant as a po-
tential source of antimalrial agents, as it is desirable to
have both activities in a potential phytodrug [48].
Although the active compound is yet to be identified,
the antimalarial activity of Croton macrostachyus could
be attributed to a single or a combination of its second-
ary metabolites such as alkaloids, flavonoids, terpenoids
and phenolic compounds. These metabolites have been
reported to have different extent of antimalarial activity
in the literature [49-51]. Many species of the genus Cro-
ton were also reported to have promising antimalarial
activity in different in vitro and in vivo studies [52,53].
In vivo antiplasmodial activity can be classified as
moderate, good, and very good if an extract displayed
percentage parasitemia suppression equal to or greater
than 50% at a dose of 500, 250 and 100 mg/kg body
weight per day, respectively [54,55]. Based on this classi-
fication, the crude extract as well as the chloroform andmethanol fractions of the studied plant showed good
antiplasmodial activity.
Conclusions
The present study indicates that 80% methanolic extract
and solvent fractions of Croton macrostachys have good
antiplasmodial activity, with varying degree and/or dif-
ferential effect on the measured parameters. The crude
extract appeared to be superior in supressing parsitemia
but was devoid of effect in protecting infected animals
from parasite-induced PCV reduction. Although the
chloroform fraction protected PCV reduction and dis-
played greater parasite suppression among the fractions,
it failed to have a benefcial effect on body weight re-
duction. The findings suggest that the phytochemicals
responsible for antimalarial activity of the plant are non-
polar to semi-polar in nature and future studies on the
plant regrading antimalarial activity should be conducted
using the crude extract. In addition, the data would pro-
vide evidence to uphold the earlier in vitro findings as
well as the claims made by the Ethiopian traditional
medicine practioners.
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